Application of signal pathway signal inhibitor or protein synthesis inhibitor or madecassic acid in preparation of drug for treating osteoporosis
user-5f8cf9244c775ec6fa691c99(2019)
Abstract
An application of a signal pathway signal inhibitor or a protein synthesis inhibitor or a madecassic acid in preparation of a drug for treating osteoporosis is disclosed. The madecassic acid inhibitsan expression of key protein-NFATc1 required for effect performance of osteoclasts through NF-[kappa]B, calcium/calmodulin-dependent kinase and MAPK three signal transduction pathways, and RANKL-induced osteoclast generation is ultimately inhibited. The application first describes and demonstrates that the madecassic acid has a satisfactory therapeutic effect on osteoporosis caused by estrogen deficiency, suggests that a natural compound madecassic acid extracted from Chinese herbal medicine has good application prospects in prevention and treatment of the osteoporosis, and provides a new option and a drug development idea for the treatment of the osteoporosis.
MoreTranslated text
Key words
Drug development,Osteoclast,Signal transduction,Protein synthesis inhibitor,MAPK/ERK pathway,Kinase,Drug,Calcium,Pharmacology,Chemistry
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined